Summary
EQUITYBITES-(C)2011 M2 COMMUNICATIONS
Speciality pharma company Meda AB (STO:MEDAA) has today reached an agreement with Novartis to acquire global rights for Elidel (pimecrolimus 1% cream) for USD420m.See the full content of this document
Extract
-Meda to Acquire Elidel for Usd420m
Elidel is a patent protected, specialty focused product for the...
See the full content of this document
Sponsored links
